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Abstract
The paper by Rachidi et al. suggests that antiplatelet drugs may play a role in ameliorating the clinical outcome in a
large series of patients with head and neck cancer managed with either surgery or radiation. Our data, as well as
confirming the results observed by the authors, enhance their clinical relevance pointing out the effect of antiplatelet
drugs in terms of locoregional control in the setting of patients with advanced head and neck cancer managed with
definitive chemo-radiotherapy.
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Previous findings on patients with head and neck
cancer exposed to antiplatelet drugs
We read with great interest the article by Rachidi et al.
[1], which indicated that higher platelet count is associ-
ated with a worse survival in head and neck squamous
cell carcinoma (HNSCC). In the same cohort the use of
antiplatelet medications was associated with a reduced
risk of death.
The authors included patients with stage I–IV HNSCC,
irrespective of treatment type (surgery, chemotherapy, or
radiation).
Case series report
We retrospectively reviewed a cohort of 58 consecutive
patients with stage III-IV larynx-hypopharynx cancer
managed with definitive chemoradiotehrapy at the Cen-
tro di Riferimento Oncologico of Aviano, Italy, between
2008 and 2012 (patients characteristics by use of anti-
platelet drugs are shown in Table 1). Kaplan-Meier ana-
lysis confirmed a survival advantage in patients who
were administered with antiplatelet medications, although
not significant because of small sample size. At a median
follow-up of 31 months, the 3-year survival of patients
who were taking antiplatelet drugs (20 patients) was 69 %
vs 54 % for those who were not taking (p = 0.12). Interest-
ingly, our data also showed a significant difference in
locoregional control (LRC) between patients who were
and were not taking antiplatelet medications during
radiotherapy (3-year LRC resulted 76 % and 45 %, re-
spectively, p = 0.01 - Fig. 1).
Since antiplatelet treatment was significantly associ-
ated to age and tumor stage, subgroup analysis were also
conducted. The same effect was observed both patients
aged <65 year (3-year LRC was 80 % vs 40 % for those
who were and were not taking antiplatelet drugs), and in
the those aged ≥65 year (74 % vs 58 %, respectively), as
well as in patients with stage III (75 % and 54 %, respect-
ively) and stage IV cancer (74 % and 40 %, respectively).
Rachidi and colleagues [1] reported stronger effect
of antiplatelet use on OS in patients with thrombocy-
tosis. In our study, we also found a greater advantage
from antiplatelet use among patients with platelet
count >250.000/μL (Table 1) in both OS (3-year OS:
63 % vs 43 % in antiplatelet users and non users, p =
0.50) and LRC (3-year LRC : 71 % vs 18 %, p = 0.02).
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Comment
Our results confirmed that the use of antiplatelet medi-
cations modify outcomes in patients with HNSCC. LRC
is recognized as a surrogate endpoint of survival for pa-
tients with locally-advanced HNSCC [2], and our find-
ings concerning LRC may be translated into survival at
longer follow-up, confirming the results published in
the paper. Moreover, these elements concerning the ef-
fects on LRC suggest that antiplatelet medications may
have a role in enhancing the efficacy of radiation for
HNSCC and indicate the strong need for a randomized
clinical trial.
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Fig. 1 Locoregional control of 58 advanced larynx-hypopharynx cancer patients by use of antiplatelet drugs
Table 1 Baseline socio-demographic and clinical characteristics
of 58 larynx-hypopharynx cancer patients, according to regular
antiplatelets use
Non-Antiplatelets users Antiplatelets users Fisher
exact testN (%) n (%)
Sex
Men 34 (89.5) 16 (80.0) p = 0.43
Women 4 (10.5) 4 (20.0)
Age (years)
<65 28 (73.7) 5 (25.0) p <0.01
≥65 10 (26.3) 15 (75.0)
Tobacco smoking
Never 5 (13.2) 4 (20.0) p = 0.70
Ever 33 (86.8) 16 (80.0)
T status
T2–T3 27 (71.0) 20 (100.0) p = 0.01
T4 11 (29.0) 0 (0.0)
N status
N0 11 (29.0) 8 (40.0) p = 0.56
N1–N3 27 (71.0) 12 (60.0)
Stage
III 13 (34.2) 15 (75.0) p <0.01
IV 25 (65.8) 5 (25.0)
Platelet count at radiotherapy beginning (cells/μL)
<250.000 19 (51.3) 11 (57.9) p = 0.78
≥250.000 18 (48.7) 8 (42.1)
Locoregional recurrence
No 17 (44.7) 16 (80.0) p = 0.01
Yes 21 (55.3) 4 (20.0)
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Institute, Aviano, Italy. 4Department of Surgery, Centro di Riferimento
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